Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Feingold syndrome type 1 (FS1) is a rare inherited malformation syndrome characterized by microcephaly, short stature and numerous digital anomalies.
Features include always present findings: Short middle phalanx of finger; and common findings: Mild intellectual disability, Short palpebral fissure, Esophageal atresia, and 4-5 toe syndactyly and others. 45 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Head and neck | 5 | High palate, Microcephaly, Everted lower lip vermilion |
Brain and nerves | 4 | Mild intellectual disability, Depressed nasal tip, Specific learning disability |
Arms and legs | 4 | 4-5 toe syndactyly, 2-3 toe syndactyly, Short middle phalanx of finger |
Digestive system | 3 | Accessory spleen, Esophageal atresia, Gastrointestinal atresia |
Heart and blood vessels | 2 | Interrupted aortic arch, Ventricular septal defect |
Ears | 1 | Hearing loss (hearing impairment) |
Pregnancy and birth | 1 | Decreased fetal movement |
Age of onset: at birth.
Feingold syndrome 1 (FS1) as described by and is characterized by digital anomalies, microcephaly, facial dysmorphism, gastrointestinal atresias, and learning disability. To date, 69 families with 116 affected individuals having three or more of the core features of FS1 (brachymesophalangy, toe syndactyly, microcephaly, short palpebral fissures, and intestinal atresia) have been reported . Features are summarized in . Table 2. Features in Feingold Syndrome 1 (FS1) Feature | % of Persons w/Feature Digital anomalies
Brachymesophalangy | 100% |
|---|---|
Facial dysmorphism | Short palpebral fissures |
Atresia | Esophageal |
Other | Renal abnormalities |
Source: GeneReviews — "Feingold Syndrome 1"
MYCN encodes MYCN proto-oncogene, bHLH transcription factor (464 aa). Positively regulates the transcription of MYCNOS in neuroblastoma cells Highest expression in Nerve Tibial (7.5 TPM) and Testis (6.8 TPM).
Feingold syndrome type 1 is associated with mutations in the MYCN gene on chromosome 2.
The MYCN protein participates in ALK-stimulated MYCN gene expression, MYC/MYCN bind the ALK gene, and MYC,MYCN binding to CD274 gene pathways.
MYCN is classified as a druggable target (Clinically Actionable and Drug Resistance categories) with score 5.0.
No significant differences are observed among individuals with deletions or missense, nonsense, or frameshift variants.
Source: GeneReviews — "Feingold Syndrome 1"
The penetrance for major features of FS1, especially digital abnormalities, appears to be 100% but clinical expression can vary considerably.
Source: GeneReviews — "Feingold Syndrome 1"
Feingold syndrome 1 (FS1) should be suspected in probands with the following clinical findings .
Digital anomalies (brachymesophalangy, thumb hypoplasia, toe syndactyly)
Microcephaly (occipito-frontal circumference 10th centile)
Short palpebral fissures
Gastrointestinal atresias, especially esophageal and duodenal, diagnosed pre- or postnatally by imaging studies (usually ultrasound examination, possibly MRI)
The diagnosis of FS1 is established in a proband with suggestive clinical findings and a heterozygous pathogenic (or likely pathogenic) variant in MYCN identified by molecular genetic testing . Note: (1) Large contiguous-gene deletions encompassing MYCN and other genes have been reported in individuals with features of FS1 but more complex ph...
Source: GeneReviews — "Feingold Syndrome 1"
Table 3. Other Genes of Interest in the Differential Diagnosis of Feingold Syndrome 1 (FS1)
Gene(s) | Disorder | MOI | Clinical Features of Differential Diagnosis Disorder |
|---|---|---|---|
CHARGE syndrome | AD | Esophageal atresia; Heart defects; Renal abnormalities | Coloboma; Genital abnormalities |
Ear anomalies MIR17HG1 | Feingold syndrome 2(OMIM 614326) | AD |
Genetic testing for MYCN is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Feingold syndrome type 1 has been reported in the published literature.
No approved treatments are currently available for Feingold syndrome type 1. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with Feingold syndrome 1 (FS1), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with Feingold Syndrome 1 (FS1)
System/Concern | Evaluation | Comment |
|---|---|---|
Hands/Feet | Assess for digital anomalies. | Hand surgeon; Occupational therapy to assess hand function/ need for therapy; Foot specialist to assess for functional needs |
Gastrointestinal tract | Assess for gastrointestinal atresia (incl esophageal, duodenal, jejunal, anal). | Gastroenterologist/ GI surgeon |
Development | Developmental assessment | Incl eval of motor, speech-language, general cognitive, vocational skills |
Renal abnormalities | Renal ultrasound eval | Assess for renal anomalies. |
Cardiac abnormalities | Assess for congenital heart defects. | Pediatric cardiologist |
Hearing loss | Audiologic eval1 | Conductive sensorineural |
Miscellaneous | Consultation w/clinical geneticist /or genetic counselor | 1. See Hereditary Hearing Loss and Deafness Overview for details about audiologic evaluations. |
Source: GeneReviews — "Feingold Syndrome 1"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Feingold Syndrome 1"
View trials for Feingold syndrome type 1
Table 5. Recommended Surveillance for Individuals with Feingold Syndrome 1
System/Concern | Evaluation | Frequency |
|---|---|---|
Hands/Feet | Hand function / need for OT | Per OT |
GI tract atresia | As specified by GI consultants | Per GI consultants Development/ |
Education | Monitor developmental progress educational needs. | Routinely, per developmental pediatrician /or school |
Renal | As specified by renal consultants | Per renal consultants |
Cardiac | As specified by cardiac consultants | Per cardiologist |
Hearing | Audiologic reexamination to determine type extent of hearing loss success w/hearing habilitation | Per treating audiologist GI = gastrointestinal; OT = occupational therapist/therapy |
Source: GeneReviews — "Feingold Syndrome 1"
Phenotype severity distribution: 1 always present feature, 8 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Feingold syndrome type 1.
55 publications have been identified in PubMed for Feingold syndrome type 1. Research spans Basic Science / Preclinical (31%), Clinical Trial Publication (25%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 17 | 31% |
Clinical study results | 14 | 25% |
Disease patterns and progression | 8 | 15% |
Patient case studies | 7 | 13% |
Research summaries | 4 | 7% |
New treatment approaches | 3 | 5% |
Testing and diagnosis research | 2 | 4% |
Choi SB (2026). [PMID: 41992837](https://pubmed.ncbi.nlm.nih.gov/41992837/). *Top Stroke Rehabil*. [Epidemiology / Natural History]
Šáhó R (2026). [PMID: 41928800](https://pubmed.ncbi.nlm.nih.gov/41928800/). *Res Sq*. [Case Report / Case Series]
Sacchetto L (2026). [PMID: 41403717](https://pubmed.ncbi.nlm.nih.gov/41403717/). *Lancet regional health. Americas*. [Epidemiology / Natural History]
Carli L (2026). [PMID: 41176342](https://pubmed.ncbi.nlm.nih.gov/41176342/). *The Journal of rheumatology*. [Clinical Trial Publication]
Javier Mérida De la Torre F (2026). [PMID: 42195009](https://pubmed.ncbi.nlm.nih.gov/42195009/). *Genes (Basel)*. [Basic Science / Preclinical]
Weijers JAM (2026). [PMID: 42066686](https://pubmed.ncbi.nlm.nih.gov/42066686/). *ESMO Open*. [Basic Science / Preclinical]
Tzeravini E (2026). [PMID: 41575482](https://pubmed.ncbi.nlm.nih.gov/41575482/). *Current obesity reports*. [Diagnostic / Biomarker]
Yu M (2026). [PMID: 41407150](https://pubmed.ncbi.nlm.nih.gov/41407150/). *Journal of dentistry*. [Basic Science / Preclinical]
Dehghani L (2026). [PMID: 41218735](https://pubmed.ncbi.nlm.nih.gov/41218735/). *Diabetes & metabolism*. [Clinical Trial Publication]
Retuerto-Guerrero M (2026). [PMID: 41400930](https://pubmed.ncbi.nlm.nih.gov/41400930/). *Rheumatology (Oxford, England)*. [Review / Meta-Analysis]
Data assembled from 7 of 12 sources · Last updated Sep 18, 2026, 5:45 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Feingold syndrome type 1
Microcephaly; Mild growth delay; Brachymesophalangy, toe syndactyly, thumb hypoplasia; Learning disabilities
Fanconi anemia | ARADXL | Thumb hypoplasia; Microcephaly; Growth restriction; Intestinal/anal atresia; Renal abnormalities | Absence of brachymesophalangy / toe syndactyly; tumor risk (not found in FS1) AD = autosomal dominant; AR = autosomal recessive; MOI = mode of inheritance; XL = X-linked 1. Feingold syndrome 2 is caused by hemizygous deletions of chromosome 13q31.3 including MIR17HG . 2. |
Source: GeneReviews — "Feingold Syndrome 1"